Clinical Pharmacology Aspects of Chimeric Antigen Receptor (CAR)-TCell Therapy Development

抄録

With potentially "single dosing curative paradigm" promised by CAR-Ttherapies there is a paradigm shift in the treatment and management ofhematologic malignancies, and the field is rapidly evolving. US FDA approvedCAR-T therapies now extend beyond CD-19 targeting CAR Ts to also include themost recently approved BCMA CAR-T for relapsed refractory multiple myeloma.Advancements in the field are also being made towards reducing the long anddifficult wait for critically ill patients with "off-the shelf"allogenic CAR-T therapies now in various stages of clinical development. Frominitial focus to only hematologic malignancies, indications are now broadeningto solid tumors with a focus on TCR-T therapies for solid tumors in clinicaldevelopment. There are unique clinical pharmacology and biopharmaceutic aspectsof development of CAR-T therapies that offer challenges yet great opportunitiesfor optimization of the clinical development for this important class oftherapies. This oral presentation will highlight those.